Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Bullpen Parlay Acquisition Company Announces Availability of Annual Report on Form 10-K
March 30, 2023 23:59 ET
|
Bullpen Parlay Acquisition Company
SAN FRANCISCO, March 30, 2023 (GLOBE NEWSWIRE) -- Bullpen Parlay Acquisition Company (Nasdaq: BPAC) (the “Company”) yesterday announced the filing of its annual report on Form 10-K for the fiscal...
Australian Prime Minister Anthony Albanese Visits Tritium
March 30, 2023 21:40 ET
|
Tritium DCFC Limited
BRISBANE, Australia, March 30, 2023 (GLOBE NEWSWIRE) -- Tritium DCFC Limited (Tritium) (Nasdaq: DCFC), a global leader in direct current (DC) fast chargers for electric vehicles (EVs), welcomed...
Bonso Reports Half Year Results
March 30, 2023 20:35 ET
|
Bonso Electronics International, Inc.
HONG KONG, March 30, 2023 (GLOBE NEWSWIRE) -- Bonso Electronics International, Inc. (NASDAQ: BNSO) today announced its unaudited results for the six-month period ended September 30, 2022. Bonso...
OMNIQ ANNOUNCES RECORD BREAKING ANNUAL REVENUE OF $102.5 MILLION, $25 MILLION FOR Q4 2022 AND REACHES POSITIVE CASH FLOW FROM OPERATIONS FOR FIRST TIME
March 30, 2023 20:04 ET
|
OMNIQ Corp.
SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- OMNIQ Corp. (NASDAQ: OMQS) (“OMNIQ” or “the Company”), a provider of Artificial Intelligence (AI) and IoT – based solutions announces record...
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
March 30, 2023 20:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced...
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
March 30, 2023 20:00 ET
|
HUTCHMED (China) Limited
— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib...
Stryve Foods, Inc. Announces Timing of Fiscal 2022 Fourth Quarter and Full Year Results
March 30, 2023 19:30 ET
|
Stryve Foods, Inc.
PLANO, Texas, March 30, 2023 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snack and eating platform disrupting traditional consumer packaged...
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
March 30, 2023 19:30 ET
|
Biogen Inc.
TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
March 30, 2023 19:30 ET
|
Biogen Inc.
TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
SeaStar Medical Reports 2022 Financial Results and Provides a Business Update
March 30, 2023 19:23 ET
|
SeaStar Medical Holding Corporation
DENVER, March 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...